Table 1.
• Diabetes mellitus, defined as plasma glucose >126 mg/dL or use of antidiabetic drugs | |
• Severe chronic renal insufficiency (GFR < 30 mL/min/1.73 m2 calculated with the MDRD equation) | |
• AIDS diagnosis, conditions with short life-expectancy | |
• Consumption of design drugs within the last 5 years* | |
• Allergy to iodine or gadolinium based contrast agents | |
• Claustrophobia | |
• Metallic implants (eg pacemakers, defibrilators) | |
• Acute psychotic attack |
*Design drugs investigated were METH (methamphetamine, also called speed, crystal meth), MDA (3,4- methylenedioxyamphetamine, also known as love drug), MDMA (3,4-methylenedioxy-N-methylamphetamine, also known as ecstasy) and MDEA / MDE (3,4- methylenedioxy –N-ethylamphetamine, also called Eve).